苗翠娟

【摘要】 目的：研究雌孕激素治疗骨质疏松症患者的临床效果，并分析其用药安全性。方法：选取笔者所在医院2014年10月-2015年8月所收治的104例女性骨质疏松患者作为本次研究对象，按照抽签法对患者进行分组治疗，分为研究组和对照组，每组52例，对照组患者应用钙剂治疗，研究组患者在对照组患者的基础上加用尼尔雌醇治疗，观察两组患者的性激素水平、骨密度、子宫内膜厚度及血尿生化指标和子宫卵巢的大小。结果：研究组患者治疗后骨密度显著高于对照组，尿钙/尿肌酐及促卵泡素和雌二醇明显优于对照组，且研究组血碱性磷酸酶水平低于对照组，差异有统计学意义（P<0.05）。两组患者治疗后子宫大小、子宫内膜厚度差异无统计学意义（P>0.05），卵巢大小组间对比差异有统计学意义（P<0.05）。结论：女性骨质疏松患者应用雌孕激素治疗的效果明显，安全性较高，且不增加子宫和卵巢肿瘤的风险，值得推广应用。

【关键词】 雌孕激素； 尼尔雌醇； 骨质疏松

doi：10.14033/j.cnki.cfmr.2018.11.005 文献标识码 A 文章编号 1674-6805（2018）11-0010-03

Clinical Analysis of Estrogen and Progesterone in the Treatment of Female Osteoporosis/MIAO Cuijuan.//Chinese and Foreign Medical Research，2018，16（11）：10-12

【Abstract】 Objective：To study the clinical efficacy of estrogen and progesterone in the treatment of osteoporosis females，and to analyze the safety of drug use.Method：From October 2014 to August 2015，104 females with osteoporosis were selected as the study subjects.The patients were divided into the study group and the control group according to the lottery method.In the 52 cases，the control group was treated with calcium.The patients in the study group were treated with Nylestriol on the basis of the control group.The levels of sex hormones，bone mineral density，endometrial thickness and hematuria biochemical indexes，uterine ovarian size were observed.Result：The bone mineral density of the study group was significantly higher than that of the control group，Urinary calcium/urinary creatinine.and follicle stimulating hormone and estradiol were significantly better than those in the control group，and there were significant differences between the two groups（P<0.05），the level of blood alkaline phosphatase in the the study group was lower than the control group，which was statistically significant（P<0.05）.There was no difference in uterine size and endometrial thickness between the two groups after treatment，no statistical significance（P>0.05），and there was a significant difference between the ovarian size（P<0.05）.Conclusion：The application of estrogen and progesterone in women with osteoporosis is obvious and safe，and it can not increase the risk of uterine and ovarian tumor.It is worthy to be popularized and applied.

【Key words】 Estrogen and progesterone； Nylestriol； Osteoporosis

First-authors address：Kunming First Peoples Hospital Gan Mei International Hospital，Kunming 650000，China

骨質疏松症状多发生在老年女性中，该病症属于一种全身性的骨代谢疾病，近几年，骨质疏松症状的发病率呈现逐年上升的趋势[1]，临床中治疗骨质疏松症的方法也有很多，其中最为有效的就是应用激素治疗，基于此，本文就应用复方尼尔雌醇进行治疗，具体报告如下。

1 资料与方法

1.1 一般资料

选取笔者所在医院收治的104例女性骨质疏松患者作为研究对象，所选病例的时间为2014年10月-2015年8月，患者全部知情资源参与本次研究，均签署相关知情文件。本次研究排除认知功能障碍以及无法配合本次研究患者，纳入标准：符合疾病诊断标准；神经功能健全；无其他疾病。按照抽签法对患者进行分组，研究组和对照组各52例，所有患者均经文献[2-3]《骨质疏松骨折密度诊断标准》确诊为骨质疏松患者。……